



WoundSense

Empowering Healing. Smarter Care.



Purpose


Empower patients using tech-powered prognosis, reduce financial burden on healthcare ecosystem and .

Transform wound care through:

- continuous biomarker monitoring
- moving towards prognosis from diagnosis
- accurate measurement
- real-time healing progress

Aim to:

- reduce wound complications
- improve wound heal time
- minimize in-person visits
- save healthcare costs
- empower tele-health



The \$50B Problem We're Solving

Delayed Detection

- Infections go unnoticed for days
- Severe unintended complications
- Extended healing times

Reactive Care

- HCPs rely on visual inspection
- Patients need to go in-person
- Critical changes missed

Rising Costs

- Wound care alone in US costs \$50B
- Inability to prevent complications, a big reason for 10% YoY cost bump

Diabetic Foot Ulcers


- 25% develop infections leading to amputation risk
- Early detection could prevent 85% of amputations

Ostomy Complications

- 40% of patients experience peristomal skin issues
- 60% going undetected between visits



Massive Market Opportunity



Our practical Solution: Continuous Wound Intelligence

Multi-Analyte Film

Continuously monitors pH, moisture, ammonia, and bacterial metabolites in real-time using graphene technology

Intelligence from the edge

Inference at edge and real-time data sync to provide instant alerts and visual mapping to care providers. RTLS for remote management.

Clinical Integration

Seamlessly integrates with existing wound dressings and ostomy baseplates



Execution, Adoption & Scale

1

Clinical Validation

- Partner with leading wound care centers for diabetic foot ulcer trials
- Target 500 patient pilot studies

2

Product Market Fit (PMF)

- Approach Clinicians to build first adopters
- Leverage the CMS bundled payment models for quick reimbursement
- Demonstrate cost savings to secure coverage policies.

3

Commercial Launch

- Demonstrate trust, clinical evidence publications
- Direct sales to wound care specialists and ostomy clinics
- Partner with major dressing manufacturers

4

Scale & Expand

- Create an on-demand hardware service model
- Demonstrate cost savings to secure coverage policies
- Expand to surgical wounds, pressure ulcers, and international markets through strategic partnerships.

Competitive Advantage

Patent Moat

Aggressively planning for 3 to 4 provisional patents covering multi-analyte sensing technology, Graphene composites and algorithmic detection

Clinical Network

Exclusive partnerships with top 3 wound care centers providing unmatched validation data

On Demand Service model, self-diagnosis

Designed specifically for on demand serviceability, service pricing models, push for adoption by providers for faster healing and reduced # of touch points and trips needed for wound healing

Technical Differentiation

Only solution combining 6+ biomarkers with predictive AI algorithms, delivering 94% accuracy in infection prediction.

Market Positioning

First-to-market advantage in continuous wound monitoring with proven clinical outcomes and cost reduction.



Our Team

- Entrepreneurs with multiple exits, with 2 acquisitions completed
- 90 years of cumulative experience in progressive medical device and tech revolution experience
- Pragmatic, Passionate & Purpose-driven industry veterans
- Extraordinary fusion of industry experience with cutting edge tech advancements pedigree



Mo Morales
Head of Design



Amy Mifsud
Product Lead



Jay Madduru
Head of Engineering

Mike Krupnick
Head of Product, Healthcare

Tim Wells
Advisor & Board Member

Joel Roberts
Head of Infrastructure

Dinendra Ramachandran
Advisor & Board Chair

Cultural Values: Our Four Pillars

Together we win

- Learn Fast mindset
- Focus on our goals
- Adapt quickly to market
- Communicate constantly

Always be learning

- Stay vigilant of emerging research
- Share learnings across the team
- Constantly evolve our awareness
- Adopt tech aggressively


Stay grounded

- Ground in patient empathy and feedback
- Listen intently our patients and people
- Build with solid and capable partnerships
- Integrate with medical institutions

Be purposeful

- Respect our patients and each other
- Data-driven decisions
- Patient-centered design
- Regulatory compliance and alignment

Financial Projections




Seed: \$3M - 18 months

- FDA breakthrough device designation
- Clinical pilot studies completion
- IP portfolio expansion

Series A: \$12M - 24 months

- FDA clearance achievement
- Commercial partnerships secured
- First revenue generation


Investment Opportunity



85%

Reduce Amputations by 85%

Our AI-powered wound monitoring can dramatically reduce costly and life-altering diabetes-related amputations, a \$25B annual problem.



60%

60% Healthcare Cost Savings

By catching wounds early and preventing complications, our solution can save \$8,000 per patient annually in healthcare costs.



15x

15x Market Multiple

Successful medtech monitoring companies have achieved **15x exit** multiples on average, representing huge upside potential for investors.

Join us in revolutionizing wound care. With proven technology, an experienced team, and a clear path to market, we're positioned to capture significant value in this massive, underserved \$50B market.

\$3M Seed Fund

A Call to Action

Believe in us - we are a
committed to transformation!



Invest in WoundSense to
transform wound care with us!



Thank you for the consideration

References

<https://phys.org/news/2025-07-graphene-based-artificial-tongue-human.html>

[A matter of taste: Electronic tongue reveals AI inner thoughts | Penn State University](#)

[Graphene-based artificial tongue achieves near-human-like sense of taste](#)

[This AI powered 'tongue' can tell Coke and Pepsi apart](#)